Stem cell research has been in process for well over five decades, because stem cells have the unique ability to divide, replicate repeatedly, and differentiate into a wide variety of specialized cell types. Indeed, the possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in cell therapy, to pharmacological testing on cell-specific tissues and more.
Because the scientific community has expanded its activities involving stem cell research, there has been a growing need for high-quality cell culture products and systems. Large companies selling stem cell research products include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Lonza Group, Clontech (a Takara Bio Company), GE Healthcare Life Sciences, and others.
Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific is a global research supply company that was created in 2006 by the merger of Thermo Electron and Fisher Scientific. With a market capitalization of approximately $54 billion, Thermo Fisher Scientific is a behemoth within the stem cell marketplace.
To date, Thermo Fisher Scientific has largely relied on two primary strategies for its growth. The first strategy has been acquisitions and collaborations, while the second strategy has been education. The focus of this post focuses on the second strategy, that of providing high quality education to the stem cell community.
Below, Thermo Fisher Scientific releases a Cell Therapy Systems (CTS) video series featuring cell therapy developers talking about their challenges and concerns.
Cell Therapy Systems (CTS) Video Series
In this 7-part video series, Thermo Fisher Scientific asks four experts with backgrounds in stem cell therapy and immunotherapy research, cell therapy manufacturing, and clinical development to share their unique perspectives on the opportunities and challenges facing the cell therapy industry. These experts provide practical guidance and valuable insights on a range of topics critical to successfully translating cell therapy research into clinical and commercial applications.
The CTS homepage has a link to each of the 7 videos. Or, you can watch them below. Enjoy and leave your thoughts and comments in the section below.
Episode 3: Impact of Raw Materials on Cell Therapy Development
Episode 4: Improving Cell Therapy Systems with Raw Material Selection
Episode 5: Importance of Scalable Cell Therapy Manufacturing Processes
Episode 6: Benefits of Documentation in Cell Therapy Development
Episode 7: Choosing the Ideal Cell Therapy Product Supplier
To learn more about Thermo Fisher Scientific’s effort to translate cell therapy research into clinical success, visit the Cell Therapy System (CTS) product page.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.